Background: Effective treatment strategies for hepatocellular carcinoma (HCC) remain limited. Identification of additional therapies remains paramount as currently available agents have resulted in marginal improvements in overall survival or are not appropriate for this patient population.
Publications
Molecular characterization of 350 hepatocellular carcinomas identifies biomarker aberrations with potential novel therapeutic options
– Caris Life Sciences
Download Publication